J Korean Med Sci.
1995 Oct;10(5):314-317. 10.3346/jkms.1995.10.5.314.
Immunogenicity of Vi capsular polysaccharide vaccine evaluated for three years in Korea
- Affiliations
-
- 1Department of Internal Medicine, Catholic University Medical College, Seoul, Korea.
- 2Department of Pediatrics, Catholic University Medical College, Seoul, Korea.
- KMID: 644895
- DOI: http://doi.org/10.3346/jkms.1995.10.5.314
Abstract
- The immunogenicity of a single dose of Salmonella typhi(S.typhi) Vi capsular polysaccharide(CPS) vaccine was evaluated before, and at 1, 3, 12, and 36 months after vaccination. Eighty-five adults(20-28 years of age) and sixty-four children(8-16 years of age) received a single dose of 25 micrograms Vi CPS vaccine intramuscularly, and antibody titers to Vi CPS were measured by passive hemagglutination. Of 149 vaccinees, 138(92.6%) showed seroconversion at 1 month after vaccination, and then 138 out of 141(97.9%) did at 3 months. Of 137 vaccinees, 116(84.7%) maintained a persistent rise in Vi antibody titer 12 months after vaccination, and 55 out of 100(55.0%) had a 4-fold or greater rise at 36 months. No significant adverse reactions were observed. Booster injection may be needed 3-5 years after vaccination.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Safety and immunogenicity of the typhoid Vi capsular polysaccharide vaccine
- Evaluation of Immune Response for Vi-CRM(197) Conjugated Vaccine against Salmonella enterica serovar Typhi in Mice
- Haemophilus influenzae type b Vaccine
- Sleep and vaccine administration time as factors influencing vaccine immunogenicity
- Comparison of immunogenicity and safety of an influenza vaccine administered concomitantly with a 13-valent pneumococcal conjugate vaccine or 23-valent polysaccharide pneumococcal vaccine in the elderly
